171
Participants
Start Date
May 6, 2021
Primary Completion Date
May 24, 2022
Study Completion Date
May 24, 2023
INCB054707
INCB054707 will be administered once daily
Placebo
Placebo or INCB054707 will be administered once daily
Investigative Site 021, Plymouth Meeting
Investigative Site 032, Orange Park
Investigative Site 011, West Palm Beach
Investigative Site 005, Tampa
Investigative Site 022, Tampa
Investigative Site 010, Hoover
Investigative Site 004, Murfreesboro
Investigative Site 003, Columbus
Investigative Site 023, Saint Paul
Investigative Site 024, Covington
Investigative Site 007, Norman
Investigative Site 033, Dallas
Investigative Site 012, San Antonio
Investigative Site 028, Scottsdale
Investigative Site 015, Gilbert
Investigative Site 009, Los Angeles
Investigative Site 018, Los Angeles
Investigative Site 006, Irvine
Investigative Site 017, Sacramento
Investigative Site 001, Portland
Investigative Site 030, Spokane
Investigative Site 002, Brighton
Investigative Site 027, Verona
Investigative Site 020, Winnipeg
Investigative Site 014, Etobicoke
Investigative Site 034, London
Investigative Site 025, Mississauga
Investigative Site 026, North YORK
Investigative Site 031, Oakville
Investigative Site 008, Peterborough
Investigative Site 029, Québec
Lead Sponsor
Incyte Corporation
INDUSTRY